Abstract. Osteosarcoma is the most common type of primary malignant bone tumor, with extremely poor prognosis in patients with metastatic disease and resistance to therapy, such as multidrug regimens. The mechanisms of drug resistance are quite complex and have not been fully elucidated; thus, novel therapeutic targets should be identified to alleviate drug resistance in osteosarcoma. In the present study, the transcriptomes of the human osteosarcoma cell line MG63 and vincristine (VCR)-resistant MG63 cells were compared by microarray analysis. A total of 1,300 genes (602 upregulated and 698 downregulated) were reported to be differentially expressed in MG63/VCR compared with MG63 cells. Bioinformatics analysis predicted that the differentially expressed genes were mainly enriched in the B cell receptor, UVA-induced mitogen-activated protein kinases and receptor tyrosine kinase 2/3 signaling pathways. In the present study, 10 of the dysregulated genes, including roundabout homolog 1, death-associated protein kinase 1 and A-kinase anchor protein 12 were further evaluated by reverse transcription-quantitative polymerase chain reaction. These results may aid the validation of candidate biomarkers for the treatment and prognosis of osteosarcoma, and provide novel insight into the molecular mechanisms underlying the drug resistance of osteosarcoma cells.
Introduction
Osteosarcoma is the most common type of primary malignant bone tumor with a high rate of metastasis (1) . Furthermore, few biomarkers have been reported for early detection and differential diagnosis; the aggressiveness of osteosarcoma with rapid metastatic potential contributes to the poor prognosis of patients with the metastatic form of this disease (2, 3) . Multidrug regimens are used to control tumor cells at various stages of the cell cycle, eliminate local or distant micrometastases, and reduce the emergence of drug-resistant cells, which prolongs the overall and progression-free survival of patients with osteosarcoma compared with single-drug treatments, such as vincristine (VCR) (4, 5) . However, ≤40% of all human cancers develop multidrug resistance (MDR) following an initial period of response to treatment, and ~30% of osteosarcoma patients with MDR exhibit recurrence or metastasis during a five-year period (6) (7) (8) . The mechanisms of drug resistance are multifactorial, including disruption of transporter pumps, oncogenes, tumor suppressor genes, DNA repair system, mitochondrial alterations, autophagy and epithelial-mesenchymal transition (9, 10) ; however, the mechanisms underlying drug resistance are complex and require further investigation. Therefore, the associated molecular mechanisms and biomarkers should be identified.
The aim of the present study was to analyze the gene expression profiles of the human osteosarcoma cell line MG63 compared with VCR-resistant MG63 cells (MG63/VCR). These results may provide novel insight into identifying chemotherapeutic targets and developing more effective chemotherapy strategies for the treatment of osteosarcoma with VCR resistance.
Materials and methods
Cell culture. The human VCR-resistant osteosarcoma cell line MG63/VCR and its parental cell line MG63 were obtained from the Scientific Research Center, China-Japan Union Hospital of Jilin University (Jilin, China) (11) . The cells were cultured in high-glucose Dulbecco's modified Eagle's medium (H-DMEM; Invitrogen, Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; HyClone; GE Healthcare Life Sciences, Logan, UT, USA) in a humidified atmosphere with 5% CO 2 at 37˚C; three biological replicates were conducted using the MG63 and MG63/VCR cells.
Cell viability assay. The cells were suspended at a density of 8x10 3 cells per well and plated into 96-well plates in 100 µl H-DMEM supplemented with 10% FBS. Following incubation at 37˚C for 24 h, the cells were treated with VCR (New Hualian Pharmaceutical Co., Shanghai, China) at the following Identification of differentially expressed genes in MG63 osteosarcoma cells with drug-resistance by microarray analysis final concentrations: 2,000, 1,000, 500, 250, 125, and 62.5 ng/ml; drug-free medium was used as the control. MG63 cells were treated with the following concentrations: 64, 16, 4, 1, 0.25 and 0.0625 ng/ml. The half-maximal inhibitory concentration (IC 50 ) of VCR in MG63/VCR and MG63 cells was reported to be 453.4 and 0.952 ng/ml, respectively (11) . A total of two groups of cells continued to culture 48 h in drug medium at 37˚C. Cell viability was examined using 10% Cell Counting kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan) according to the manufacturer's protocols, and the cells were incubated at 37˚C for another 2 h. Subsequently, the optical density (OD) was determined by measuring the absorbance at 450 nm using a plate reader (UV8100D; LabTech, Inc., Hopkinton, MA, USA), and the inhibition ratio was calculated using the following formula: Inhibition ratio=[(OD control -OD experiment )/OD control ] x100%. Each experiment was performed in triplicate.
Total RNA extraction and microarray. Total RNA was extracted from the MG63/VCR and MG63 cells using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The quality of total RNA was determined using a NanoDrop 2000 spectrophotometer (1.7<A260/A280<2.2) and the RNA integrity (RIN) was evaluated using an Agilent Bioanalyzer 2100 (RIN≥7.0 and 28S/18S>0.7). The initial amount of total RNA (300-500 ng) was further amplified, labeled and purified by using the Microarray GeneChip 3'IVT Express kit (Affymetrix; Thermo Fisher Scientific, Inc.) According to the standard hybridization procedures and matching kit provided by Affymetrix expression chip. RNA was then subjected to treatment with the GeneChip Hybridization, Wash, and Stain kit reagent (Affymetrix; Thermo Fisher Scientific, Inc.), Rolling hybridization in a Hybridization Oven 645 for 45˚C, 16 h, and washed in GeneChip Fluidics Station 450 (Affymetrix; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocols. The results of the chip were scanned with a GeneChip Scanner 3000 system (Affymetrix; Thermo Fisher Scientific, Inc.). Differentially expressed genes in the two cell lines were determined using the fold change (FC) values. The gene expression profile was presented in Excel spreadsheets (Microsoft Corporation, Redmond, WA, USA). Volcano plot, Scatter-plot and Clustergram were used to analyze the differential gene expression. Gene set enrichment analysis was performed using Ingenuity Pathway Analysis (IPA) online software (12, 13) .
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA was extracted from the MG63/VCR and MG63 cells using TRIzol ® reagent and reverse-transcribed into cDNA using RevertAid First Strand cDNA Synthesis kit (both Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocols. The primers used for RT-qPCR were listed in Table I To systematically assign putative functions to the differentially expressed genes, bioinformatics analysis was performed with IPA. The unique statistical index of IPA is the z-score, which represents the direction and multiplier of the molecular changes under the existing experimental conditions. The z-score indicates whether the results are consistent with the references mentioned in the literature; inhibition or activation of the molecular action process was considered when |z|>2. A positive z-score suggests that the molecular interaction is activated, whereas a negative z-score indicates that the molecular interaction is inhibited.
Results

Sensitivity of MG63/VCR and MG63 cells to vincristine.
To investigate the chemosensitivity of MG63/VCR and MG63 cells to VCR, the IC 50 values in response to treatment with different VCR concentrations were determined. Following 48 h of culture in a VCR-containing medium, the IC50 value for MG63/VCR cells was significantly increased compared with that of MG63 cells (493.175±4.473 vs. 1.407±0.111 ng/ml, P=0.001), suggesting that MG63/VCR cells are more refractory to VCR compared with the parental MG63 cell line ( Fig. 1 ).
Distinct gene expression landscapes between MG63/VCR and MG63 cells.
In total, the genes that exhibited significantly aberrant expression between the two cell lines in (Table III) with statistical significance at P<0.05 and a ≥4-fold difference in expression levels between the two cell lines, were selected for further analysis. Based on their putative functions, all genes (Tables II and III) were categorized into subgroups, including transcription factors (n=2+2), enzymes (n=7+5), transporters (n=2+3), transmembrane receptors (n=1+3) and others (n=33+13).
Signaling pathways analysis.
To systematically assign putative functions to the differentially expressed genes, bioinformatics analysis was performed. Among the 800 signaling pathways identified by IPA, the major signaling pathways regulated by the differentially expressed genes were enriched in B-cell receptor signaling [including early growth response protein 1, mitogen-activated protein kinases 9 (MAPK9), cell division control protein 42 homolog and protein phosphatase 3 catalytic subunit A], ultraviolet A (UVA)-induced MAPK signaling [including phosphoinositide-3-kinase regulatory subunit 1, MAPK9 and epidermal growth factor receptor (EGFR)] and Erb-B2 receptor tyrosine kinase 2/3 (ErbB2/3) signaling pathways (including RAS related 2, signal transducer and activator of transcription 5B and serine/threonine kinase ATM; Table IV ). The first two pathways were predicted to be inhibited, while the last pathway was predicted to be promoted by VCR, suggesting that combination therapy with EGFR inhibitor and VCR may be more effective compared with single-drug therapy. The top enriched pathway was UVA-induced MAPK signaling ( Fig. 3A and B) , with a z-score of -2.309. The data, together with the predicted signaling pathways, may provide novel insight in determining whether the aberrant expression of these molecules, such as EGFR, may contribute to drug resistance.
RT-qPCR validation of differentially expressed genes.
A total of 10 of the differentially expressed genes identified by microarray analysis were selected for further validation using RT-qPCR, including six upregulated genes [multi-drug resistance gene1 (MDR1), carbonic anhydrase II (CAII), insulin-like growth factor-II binding protein 1 (IGF2BP1), A-kinase anchor protein 12 (AKAP12), roundabout homolog 1 (ROBO1) and collagen A2 (COL1A2)], and four downregulated genes, including slit guidance ligand 2, death-associated protein kinase 1 (DAPK1), fibronectin leucine rich transmembrane protein 3 (FLRT3) and testin LIM domain protein. As presented in Fig. 4 , the expression profiles of the 10 genes were consistent with the microarray data; however, the FC values varied to an extent. RT-qPCR revealed that the expression levels of FLRT3 were increased in MG63/VCR cells, which is in controversy with the microarray data. Thus, 9 of the 10 genes were positively determined by RT-qPCR.
Discussion
Personalized chemotherapy based on biomarkers may improve the sensitivity to chemotherapy and the clinical outcome of patients with cancer. Thus, investigating the molecular mechanisms underlying drug resistance is essential to develop a personalized chemotherapy regimen and prevent drug resistance during cancer therapy. In the present study, the roles of differentially expressed genes in VCR resistance of osteosarcoma cells were investigated by microarray analysis. Numerous genes determined as differentially expressed in VCR-resistant osteosarcoma cells may also be associated with VCR resistance in the present study, such as MDR1 (11) , which was upregulated in MG63/VCR cells. Previous studies have indicated that MDR1serves a key role in the proliferation and survival of epithelial and malignant cells during tumorigenesis, as well as in acquired drug resistance (15, 16) . Few of the differentially expressed genes identified in the present study, including CAII and IGF2BP1, have also been reported to promote cell invasion and drug resistance (17, 18) ; however, some results were in conflict with previous studies. For example, zinc finger E-box binding homeobox 2and chitinase (19, 20) ; this may be caused by experimental errors. Different experimental conditions, including sample types, processing methods and sampling time may result in differences in gene expression, which may also be affected by a variety of factors, such as PCR conditions and chip analysis. In addition, there is a lack of data to effectively predict the functions of some of the aberrantly expressed genes at present, including AKAP12, DAPK1 and ROBO1, which may be the potential genes associated with drug resistance; however, further investigation is required. IPA analysis can aid the investigation of novel molecular mechanisms underlying drug resistance. For example, a previous study revealed that the expression levels of COL1A2 and insulin like growth factor 1 receptor (IGF1R), along with the associated pathways, were induced in ovarian cancer cells with topotecan-and paclitaxel-resistance (21) . In addition, IGF1R-induced chemoresistance of tumor cells was associated with the signaling pathways involved in the promotion of cell proliferation, inhibition of apoptosis, regulation of ATP-binding cassette transporter proteins and interactions with the extracellular matrix (22) ; however, other mechanisms underlying drug resistance require further investigation.
Furthermore, signaling pathway analysis revealed that differently expressed genes are mainly enriched in pathways, (23) (24) (25) . For instance, B-cell receptor signaling was reported as an essential mediator of cytoskeletal reorganization, integrin clustering and environmental-mediated drug resistance (23) . A recent study revealed that the steroidal lactone withaferin A may serve as a low-toxicity addition to ERBB2-targeted therapeutics, particularly when ERBB3 induced resistance or reduced overall sensitivity (24) . Several studies have indicated that numerous proteins are involved in UVA-induced MAPK signaling, such as EGFR (P=0.003473, FC=1.95397), which was upregulated in MG63/VCR cells and maybe a key regulator in the pathways associated with VCR resistance (25, 26) . EGFR is a transmembrane tyrosine kinase receptor, and is one of the most extensively studied MDR-associated receptors (25) . Inhibition of the EGFR/HER2 signaling pathway, particularly the activity of downstream PI3K, induced a more favorable milieu for tumor immunotherapy (26) . While the UVA-induced MAPK signaling pathway was downregulated in MG63-VCR cells, EGFR was upregulated; however, the effects of this pathway on drug resistance remain unknown.
In conclusion, differentially expressed genes were identified between MG63/VCR and MG63 cells in the present study. These results revealed the potential functions of these genes, providing novel insight into their roles in drug resistance and associated pathways, which may aid the identification of novel potential targets for the treatment of osteosarcoma. 
